JP5706058B2 - 創傷治療組成物 - Google Patents
創傷治療組成物 Download PDFInfo
- Publication number
- JP5706058B2 JP5706058B2 JP2006552692A JP2006552692A JP5706058B2 JP 5706058 B2 JP5706058 B2 JP 5706058B2 JP 2006552692 A JP2006552692 A JP 2006552692A JP 2006552692 A JP2006552692 A JP 2006552692A JP 5706058 B2 JP5706058 B2 JP 5706058B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- matrix
- fibrin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 136
- 206010052428 Wound Diseases 0.000 title claims description 98
- 208000027418 Wounds and injury Diseases 0.000 title claims description 95
- 210000004027 cell Anatomy 0.000 claims description 139
- 239000011159 matrix material Substances 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 56
- 210000002950 fibroblast Anatomy 0.000 claims description 53
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 39
- 108010073385 Fibrin Proteins 0.000 claims description 36
- 102000009123 Fibrin Human genes 0.000 claims description 36
- 229950003499 fibrin Drugs 0.000 claims description 36
- 108010049003 Fibrinogen Proteins 0.000 claims description 24
- 102000008946 Fibrinogen Human genes 0.000 claims description 24
- 229940012952 fibrinogen Drugs 0.000 claims description 24
- 108090000190 Thrombin Proteins 0.000 claims description 22
- 229960004072 thrombin Drugs 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 210000003491 skin Anatomy 0.000 claims description 14
- 230000018109 developmental process Effects 0.000 claims description 13
- 238000006116 polymerization reaction Methods 0.000 claims description 13
- 238000011161 development Methods 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 108010039627 Aprotinin Proteins 0.000 claims description 11
- 229960004405 aprotinin Drugs 0.000 claims description 11
- 230000002500 effect on skin Effects 0.000 claims description 11
- 239000011888 foil Substances 0.000 claims description 11
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 210000002510 keratinocyte Anatomy 0.000 claims description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 7
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 7
- 229960000401 tranexamic acid Drugs 0.000 claims description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 230000009758 senescence Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000001698 pyrogenic effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 37
- 239000000499 gel Substances 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 19
- 102000008186 Collagen Human genes 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 15
- 239000010410 layer Substances 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- 230000029663 wound healing Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000035876 healing Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229940033618 tisseel Drugs 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000000379 polymerizing effect Effects 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000005266 casting Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000020764 fibrinolysis Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000565 sealant Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000007788 roughening Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000003953 foreskin Anatomy 0.000 description 3
- 238000011194 good manufacturing practice Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000013411 master cell bank Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010023728 Alloderm Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- -1 Okinaxobin Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 108010038522 calobin Proteins 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010056533 gabonase Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 108010090374 matriderm Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403220A GB0403220D0 (en) | 2004-02-13 | 2004-02-13 | Wound healing composition |
| GB0403220.7 | 2004-02-13 | ||
| GB0403226.4 | 2004-02-13 | ||
| GB0403226A GB0403226D0 (en) | 2004-02-13 | 2004-02-13 | Means of packaging a wound healing composition |
| US55619404P | 2004-03-25 | 2004-03-25 | |
| US55615504P | 2004-03-25 | 2004-03-25 | |
| US60/556,194 | 2004-03-25 | ||
| US60/556,155 | 2004-03-25 | ||
| GB0426252.3 | 2004-11-30 | ||
| GB0426252A GB0426252D0 (en) | 2004-11-30 | 2004-11-30 | Wound healing composition |
| US63242504P | 2004-12-01 | 2004-12-01 | |
| US60/632,425 | 2004-12-01 | ||
| PCT/GB2005/000523 WO2005079822A2 (en) | 2004-02-13 | 2005-02-14 | Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012135016A Division JP6141603B2 (ja) | 2004-02-13 | 2012-06-14 | 創傷治療組成物 |
| JP2014258639A Division JP6141821B2 (ja) | 2004-02-13 | 2014-12-22 | 創傷治癒組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007522195A JP2007522195A (ja) | 2007-08-09 |
| JP2007522195A5 JP2007522195A5 (enExample) | 2008-04-10 |
| JP5706058B2 true JP5706058B2 (ja) | 2015-04-22 |
Family
ID=34891423
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552692A Expired - Fee Related JP5706058B2 (ja) | 2004-02-13 | 2005-02-14 | 創傷治療組成物 |
| JP2012135016A Expired - Fee Related JP6141603B2 (ja) | 2004-02-13 | 2012-06-14 | 創傷治療組成物 |
| JP2014258639A Expired - Fee Related JP6141821B2 (ja) | 2004-02-13 | 2014-12-22 | 創傷治癒組成物 |
| JP2015075997A Pending JP2015134815A (ja) | 2004-02-13 | 2015-04-02 | 創傷治療組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012135016A Expired - Fee Related JP6141603B2 (ja) | 2004-02-13 | 2012-06-14 | 創傷治療組成物 |
| JP2014258639A Expired - Fee Related JP6141821B2 (ja) | 2004-02-13 | 2014-12-22 | 創傷治癒組成物 |
| JP2015075997A Pending JP2015134815A (ja) | 2004-02-13 | 2015-04-02 | 創傷治療組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8765169B2 (enExample) |
| EP (2) | EP1718317A1 (enExample) |
| JP (4) | JP5706058B2 (enExample) |
| AU (2) | AU2005215213C1 (enExample) |
| CA (2) | CA2555233A1 (enExample) |
| WO (2) | WO2005079821A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
| US8779053B2 (en) | 2003-08-25 | 2014-07-15 | Dow Global Technologies Llc | Coating compositions |
| US8722787B2 (en) | 2003-08-25 | 2014-05-13 | Dow Global Technologies Llc | Coating composition and articles made therefrom |
| US9169406B2 (en) | 2003-08-25 | 2015-10-27 | Dow Global Technologies Llc | Coating compositions |
| US8946329B2 (en) | 2003-08-25 | 2015-02-03 | Dow Global Technologies Llc | Coating compositions |
| US11298453B2 (en) | 2003-10-28 | 2022-04-12 | Smith & Nephew Plc | Apparatus and method for wound cleansing with actives |
| AU2005215213C1 (en) | 2004-02-13 | 2011-04-28 | Smith & Nephew Orthopaedics Ag | Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
| GB0508531D0 (en) | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
| US7753894B2 (en) | 2004-04-27 | 2010-07-13 | Smith & Nephew Plc | Wound cleansing apparatus with stress |
| GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
| CN100402097C (zh) * | 2006-07-24 | 2008-07-16 | 暨南大学 | 琼脂/胶原皮肤创伤修复敷料及其制备方法和应用 |
| FR2917629B1 (fr) * | 2007-06-22 | 2009-09-11 | Oreal | Utilisation cosmetique de proteines de type apolipoproteine d |
| WO2009045543A1 (en) * | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Treatment of conditions related to shock |
| GB2457870A (en) | 2007-12-21 | 2009-09-02 | Intercytex Ltd | Wound Dressing Applicator |
| US8580314B2 (en) * | 2008-11-04 | 2013-11-12 | Stratatech Corporation | Dried and irradiated skin equivalents for ready use |
| WO2011023843A2 (es) * | 2009-08-25 | 2011-03-03 | Servicio Andaluz De Salud | Elaboración de tejidos artificiales mediante ingeniería tisular utilizando biomateriales de fibrina y agarosa |
| EP2621521A4 (en) | 2010-10-02 | 2014-04-23 | Univ California | MINIMIZING DARMDYS FUNCTIONS |
| WO2012085298A1 (es) * | 2010-12-22 | 2012-06-28 | Universidad De Valladolid (40%) | Gel de fibrina que contiene células del limbo esclerocorneal y su uso en bioingeniería de la superficie ocular |
| FR2999083B1 (fr) * | 2012-12-12 | 2015-01-23 | Univ Nantes | Pansement contenant des fibroblastes et des keratinocytes foetaux |
| CN110551424B (zh) | 2012-12-28 | 2022-07-29 | 陶氏环球技术有限责任公司 | 涂料组合物和由其制成的物品 |
| BR112015015408B1 (pt) | 2012-12-28 | 2021-07-20 | Dow Global Technologies Llc | Composição de revestimento, e, artigo revestido |
| RU2015152082A (ru) | 2013-05-10 | 2017-06-16 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Соединитель для текучей среды для орошения и аспирации ран |
| US20160213714A1 (en) * | 2015-01-23 | 2016-07-28 | Everon Biosciences, Inc. | Induction of cellular senescence for tissue therapies |
| GB201504124D0 (en) | 2015-03-11 | 2015-04-22 | Proqr Therapeutics B V | Oligonucleotides |
| RU2657202C1 (ru) * | 2017-06-13 | 2018-06-08 | Государственное бюджетное учреждение здравоохранения "Научно-исследовательский институт - краевая клиническая больница имени профессора С.В. Очаповского" Министерства Здравоохранения Краснодарского края (ГБУЗ "НИИ-ККБ N 1 им. проф. Очаповского" Минздрава Краснодарского края | Способ кожной аутопластики |
| RU2702152C1 (ru) * | 2018-11-15 | 2019-10-04 | Государственное бюджетное учреждение здравоохранения "Научно-исследовательский институт - краевая клиническая больница N 1 имени профессора С.В. Очаповского" Министерства здравоохранения Краснодарского края (ГБУЗ "НИИ-ККБ N 1 им. проф. Очаповского" Минздрава Краснодарского края) | Способ лечения донорской раны живота |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| CN111614010B (zh) * | 2020-05-12 | 2021-04-13 | 中国长江电力股份有限公司 | 500kV焊接型GIL管道母线分解检修方法 |
| JP7486227B2 (ja) * | 2020-06-30 | 2024-05-17 | 株式会社 レオロジー機能食品研究所 | 皮膚改善用組成物 |
| CN113967128B (zh) * | 2020-07-24 | 2023-04-25 | 烟台蓝创生物技术有限公司 | 一种去除海藻酸盐敷料中热原的方法 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU615414B2 (en) | 1986-04-18 | 1991-10-03 | Marrow-Tech Incorporated | Process for replicating bone marrow |
| US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| FR2597499A1 (fr) | 1986-04-18 | 1987-10-23 | Merieux Inst | Procede de culture microbiologique sur supports de collagene, supports pour ce procede et produits obtenus |
| US4837379A (en) | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| US7208179B1 (en) * | 1990-11-27 | 2007-04-24 | The American National Red Cross | Methods for treating disease and forming a supplemented fibrin matrix |
| DE4127570A1 (de) | 1991-08-21 | 1993-02-25 | Battelle Institut E V | Verfahren zur lokalen antibakteriellen therapie von wunden |
| RU2023424C1 (ru) | 1993-01-13 | 1994-11-30 | Научно-производственный центр трансплантации и культивирования тканей | Способ лечения раны |
| US5591444A (en) | 1995-07-28 | 1997-01-07 | Isolagen Technologies, Inc. | Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects |
| AU6661698A (en) | 1997-02-20 | 1998-09-09 | Gregory S. Keller | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
| JP3333108B2 (ja) | 1997-04-08 | 2002-10-07 | 学校法人東海大学 | 上皮性組織移植片およびその製造方法 |
| AU8224598A (en) | 1997-06-26 | 1999-01-19 | Smith & Nephew Plc | Cell culture products |
| US6150505A (en) * | 1997-09-19 | 2000-11-21 | Hadasit Medical Research Services & Development Ltd. | Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII |
| EP1056413A4 (en) | 1998-02-27 | 2003-08-20 | Bioelastics Res Ltd | INJECTABLE IMPLANTS FOR TISSUE ENHANCEMENT AND RESTORATION |
| AU3118499A (en) | 1998-04-03 | 1999-10-25 | Beth Israel Deaconess Medical Center | Soft tissue reconstructor and method of use |
| US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
| JP4606583B2 (ja) | 1998-06-05 | 2011-01-05 | オルガノジェネシス インク． | 生物工学的手法による平面シート状移植補綴 |
| US6699287B2 (en) | 1998-09-24 | 2004-03-02 | Korea Atomic Energy Research Institute | Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix |
| US6124522A (en) | 1998-11-24 | 2000-09-26 | Schroeder; Mark R. | Packaging for adhesive-sided articles to allow one-handed application |
| EP1137380B1 (en) | 1998-11-25 | 2004-03-31 | Coloplast A/S | A layered product ready for non-touch application and a method for producing such a product |
| RU2195889C2 (ru) | 1999-05-24 | 2003-01-10 | Парамонов Борис Алексеевич | Способ дермабразии |
| US6733530B1 (en) | 1999-08-02 | 2004-05-11 | Eric Sun-Yin Chan | Material and method for engraftment of a composite biocompatible skin graft on the neodermis of artificial skin |
| US6699470B1 (en) | 1999-10-12 | 2004-03-02 | Massachusetts Institute Of Technology | Mesh-gel constructs for cell delivery containing enzymes and/or enzyme inhibitors to control gel degradation |
| WO2001032129A2 (en) | 1999-11-05 | 2001-05-10 | Gerigene Medical Corporation | Augmentation and repair of age-related soft tissue defects |
| US6623728B2 (en) * | 2000-06-30 | 2003-09-23 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Cosmetic skin care compositions and containing gum mastic |
| DE10041468C1 (de) * | 2000-08-23 | 2002-03-07 | Surface Care Gmbh | Hautmatrix zur Abdeckung und Regenerierung verletzter Hautpartien sowie Verfahren zu ihrer Herstellung |
| US7144729B2 (en) | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
| AU9109201A (en) * | 2000-09-18 | 2002-03-26 | Organogenesis Inc | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
| ES2173812B1 (es) | 2001-03-01 | 2003-12-16 | Ct Investig Energeticas Ciemat | Dermis artificial y metodo de obtencion. |
| GB0105899D0 (en) * | 2001-03-09 | 2001-04-25 | Intercytex Ltd | Fibrosis reduction treatment |
| DE10116362A1 (de) * | 2001-04-02 | 2002-10-10 | Biotissue Technologies Ag | Zwei-Komponenten Zusammensetzungen zur in situ Herstellung v. Fibroblasten und Keratinozyten umfassenden Zelltransplantaten |
| US20030069639A1 (en) | 2001-04-14 | 2003-04-10 | Tom Sander | Methods and compositions for repair or replacement of joints and soft tissues |
| US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
| US20030166274A1 (en) | 2001-11-15 | 2003-09-04 | Hewitt Charles W. | Three-dimensional matrix for producing living tissue equivalents |
| WO2003084385A2 (en) | 2002-04-02 | 2003-10-16 | William Marsh Rice University | Redifferentiated cells for repairing cartilage defects |
| DE10217779A1 (de) | 2002-04-18 | 2003-11-13 | Co Don Ag | Konservierte Gewebematrix eines Hohlorganes, insbesondere eines Blutgefäßes, Verfahren zur Herstellung und Verwendung dieser |
| US20040082063A1 (en) | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
| AU2005215213C1 (en) | 2004-02-13 | 2011-04-28 | Smith & Nephew Orthopaedics Ag | Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds |
| RU2273457C2 (ru) | 2004-06-01 | 2006-04-10 | Сергей Степанович Кузнецов | Способ лечения грыж передней брюшной стенки |
-
2005
- 2005-02-14 AU AU2005215213A patent/AU2005215213C1/en not_active Ceased
- 2005-02-14 CA CA002555233A patent/CA2555233A1/en not_active Abandoned
- 2005-02-14 EP EP05708330A patent/EP1718317A1/en not_active Withdrawn
- 2005-02-14 WO PCT/GB2005/000511 patent/WO2005079821A1/en not_active Ceased
- 2005-02-14 WO PCT/GB2005/000523 patent/WO2005079822A2/en not_active Ceased
- 2005-02-14 CA CA2556098A patent/CA2556098C/en not_active Expired - Fee Related
- 2005-02-14 EP EP05764678.8A patent/EP1718318B1/en not_active Expired - Lifetime
- 2005-02-14 US US10/589,150 patent/US8765169B2/en not_active Expired - Fee Related
- 2005-02-14 JP JP2006552692A patent/JP5706058B2/ja not_active Expired - Fee Related
- 2005-02-14 US US10/589,227 patent/US9526746B2/en not_active Expired - Fee Related
- 2005-02-14 AU AU2005215211A patent/AU2005215211B2/en not_active Ceased
-
2012
- 2012-06-14 JP JP2012135016A patent/JP6141603B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-15 US US14/279,057 patent/US9248153B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258639A patent/JP6141821B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-02 JP JP2015075997A patent/JP2015134815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2556098A1 (en) | 2005-09-01 |
| AU2005215213C1 (en) | 2011-04-28 |
| WO2005079822A2 (en) | 2005-09-01 |
| WO2005079822A3 (en) | 2005-11-03 |
| US9526746B2 (en) | 2016-12-27 |
| AU2005215211B2 (en) | 2011-11-03 |
| AU2005215211A1 (en) | 2005-09-01 |
| JP2015063555A (ja) | 2015-04-09 |
| US9248153B2 (en) | 2016-02-02 |
| EP1718318A2 (en) | 2006-11-08 |
| JP6141603B2 (ja) | 2017-06-07 |
| US20140335183A1 (en) | 2014-11-13 |
| WO2005079821A1 (en) | 2005-09-01 |
| CA2555233A1 (en) | 2005-09-01 |
| JP6141821B2 (ja) | 2017-06-07 |
| EP1718317A1 (en) | 2006-11-08 |
| JP2015134815A (ja) | 2015-07-27 |
| JP2012192206A (ja) | 2012-10-11 |
| US20080193507A1 (en) | 2008-08-14 |
| JP2007522195A (ja) | 2007-08-09 |
| US20080226720A1 (en) | 2008-09-18 |
| US8765169B2 (en) | 2014-07-01 |
| CA2556098C (en) | 2015-11-24 |
| EP1718318B1 (en) | 2014-08-13 |
| AU2005215213B2 (en) | 2010-09-09 |
| AU2005215213A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141603B2 (ja) | 創傷治療組成物 | |
| JP4522667B2 (ja) | 組織再生のための方法および組成物 | |
| JP3646882B2 (ja) | ヒアルロン酸誘導体を基本とするバイオ適合性物質を支持体として含む人工皮膚 | |
| EP2603247B1 (en) | Fibrin based scaffold, preparation and use thereof | |
| US20060240555A1 (en) | Fibrin cell supports and method of use thereof | |
| JP2010209110A (ja) | 増殖因子を用いて、および生物学的マトリクスあるいは支持構造を用いて細胞を増殖および分化する方法およびデバイス | |
| CN111867644A (zh) | 用于治疗疾病的可植入的细胞敷料 | |
| ES2519815T3 (es) | Composición para cicatrización de heridas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120614 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120814 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121005 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131211 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150226 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5706058 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |